Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer

Trial Details

NCT ID

NCT06532617

Phase

PHASE2

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

• Cadonilimab+S-1or Capecitabine

Locations (sample)

• Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

• Signed written informed consent
• Age 18-80, female or male
• Histopathologically confirmed pancreatic ductal adenocarcinoma
• Patients with locally advanced pancreatic cancer who have previously received standard first-line anti-tumor treatment (radiotherapy, chemotherapy,…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.